Endocrine/metabolicNew toxicology data support advancement of Neumora Therapeutics’ NMRA-215Neumora Therapeutics Inc. has reported preclinical toxicology results from NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity and cardiometabolic disease.